Scientific Posters, Presentations and Publications

13th World Congress for Hair Research

• Abstract P007: A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Severe to Very-Severe Alopecia Areata (Rezolve AA)

2023 EADV Congress

• Abstract 6685: Efficacy and Safety of Single Agent Rezpegaldesleukin, a Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from a Randomized Phase 1b Study
• Abstract P0559: A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis

2022 EADV Congress

• Abstract P1242: Efficacy and Safety of a Selective Regulatory T-Cell Inducing IL-2 Conjugate (LY3471851) in the Treatment of Atopic Dermatitis: A Phase 1 Randomised Study
• Abstract P1611: Efficacy and Safety of a Selective Regulatory T-Cell Inducing IL-2 Conjugate (LY3471851) in the Treatment of Psoriasis: A Phase 1 Randomised Study

2021 Journal of Translational Autoimmunity

• Publication: NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases

2020 ACR Convergence 2020 Meeting

• Presentation: NKTR-358: Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate

2020 European E-Congress of Rheumatology (EULAR)

• Presentation: NKTR-358: A PEG-conjugated rhIL-2 that selectively induces Tregs and their suppressive activity

The Promise of Interleukin-2 Therapy Meeting, Paris, France

• Presentation: Selective Expansion of Regulatory T-Cells by a Novel IL-2 Conjugate, NKTR-358, Being Developed for the Treatment of Autoimmune Diseases, Christie Fanton, PhD

2019 EULAR European Congress of Rheumatology

2019 American College of Rheumatology Annual Meeting

• Abstract 98: “Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases”, Fanton, C., et al.

2019 EULAR European Congress of Rheumatology

• Oral Presentation: Selective Expansion of Regulatory T-Cells in Humans by a Novel IL-2 Conjugate T-reg Stimulator, NKTR-358, Being Developed for the Treatment of Autoimmune Diseases, Brian Kotzin, M.D.

Treg Directed Therapy for Autoimmune Disorders Meeting – May 2018

• Presentation: NKTR-358: An IL-2 Pathway Agonist that Selectively Expands and Activates Regulatory T cells for the Treatment of Allergy and Autoimmune Disease

Antigen-Specific Immune Tolerance Drug Development Summit – April 2018

• Presentation: NKTR-358: A Selective Regulatory T Cell Inducing Agent for the Treatment of Autoimmune and Inflammatory Diseases

American College of Rheumatology Annual Meeting, San Diego, CA

• Poster Abstract 2715: NKTR-358: A Selective, First-in-Class IL-2 Pathway Agonist Which Increases Number and Suppressive Function of Regulatory T Cells for the Treatment of Immune Inflammatory Disorders, Langowski, J., et al.

13th Annual World Congress on Inflammation

• Presentation: NKTR-358: a selective, first-in-class IL-2 pathway agonist which increases number and suppressive function of regulatory T cells for the treatment of immune inflammatory disorders

64th American Society of Hematology (ASH) Annual Meeting & Exposition

• Poster 4652: Safety, Tolerability, PK/PD, and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
• Poster 3335: A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multi-center Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCTTM and CIBMTR®

• Presentation (Abstract 27): “Targeting Ewing sarcoma, Osteosarcoma and Neuroblastoma with Anti-MCAM Chimeric Antigen Receptor Modified Natural Killer Cells” Luo, W., et al.
  • Poster Presentation
• Poster (Abstract 201): “Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell- Mediated Cytotoxicity Combined with anti-CD20 or anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL)” Chu, Y., et al.

63rd American Society of Hematology (ASH) Annual Meeting & Exposition

• Poster 3134: Safety, Tolerability, PK/PD, and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
• Poster 2815: Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8+ T-cells: Preliminary Results from a Phase 1 Study

2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Poster 957: NKTR-255 + Cetuximab in Patients with Solid Tumors: Interim Safety and Efficacy Results from the Phase 1b Dose-escalation Study

2021 European Society for Medical Oncology (ESMO) Congress

• TiP Poster 1026TiP: Phase 1b/2, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors

2021 Future Oncology

• Publication: Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies

2021 Journal for ImmunoTherapy of Cancer

• Publication: NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy

62nd American Society of Hematology (ASH) Annual Meeting & Exposition

• Abstract 667: Restoring NK Cell Activities in Multiple Myeloma with IL-15 Receptor Agonist NKTR-255, Fernández, F., et al.
• Abstract 825: Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL), Chu, Y., et al.

2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Abstract 355: First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies, Shah, N., et al.

61st American Society of Hematology (ASH) Annual Meeting & Exposition, Orlando, FL

• Abstract 2866: Combination of NKTR-255, a polymer conjugated human IL-15, with CD19 CAR T cell immunotherapy in a preclinical lymphoma model, Chou, C., et al.
• Abstract 4398: Restoring innate and adaptive immune repertoire in multiple myeloma for therapeutic application, Fernandez, R., et al.
• TiP Abstract 4459: A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma, Shah, N., et al.

2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Abstract P619: NKTR-255, a polymer-conjugated IL-15 receptor agonist, enhances efficacy of therapeutic monoclonal antibodies with ADCC activity in solid tumor models, Kivimäe, S., et al.
• Abstract P622: Characterization and comparison of NKTR-255, a polymer-conjugated IL-15 versus IL-15 superagonist, Miyazaki, T., et al.

4th Congress of European Hematology Association (EHA)

• Abstract # PS1208: Effects Of NKTR-255, A Polymer Conjugated Human IL-15, on Efficacy of CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model, Chou, C., et al.

AACR 2019

• Abstract 3265/Poster Board 15: NKTR-255, a polymer-conjugated IL-15 enhances anti-tumor NK cell responses and synergizes with monoclonal antibodies to provide long-term survival in human lymphoma model, Miyazaki, T., et al.

2018 ASH 60th Annual Meeting

• Pharmacokinetic and Pharmacodynamic Study of NKTR-255, a Polymer-Conjugated Human IL-15, in Cynomolgus Monkey, Miyazaki, T., et al.

SITC 2018

• Abstract #418: Pre-clinical investigation of NKTR-255, a polymer-conjugated IL-15 with a potent NK cell dependent anti-tumor efficacy, Miyazaki, T., et al.
• Abstract #422: A polymer-associated human IL-15 (NKTR-255) has optimized biological activity and unique mechanisms of action on CD8 T Cells and NK Cells, Robinson T., et al.

2018 American Conference on Pharmacometrics (ACoP), San Diego, CA

• Poster T-039: NKTR-255 Exhibits Target Mediated Drug Disposition and Stimulates Proliferation of Cytotoxic Immune Cells in Cynomolgus Monkeys

CHI 3rd Annual NK Cell-Based Cancer Immunotherapy Conference, Boston, MA

• NKTR-255: Accessing the Immunotherapeutic Potential of IL-15 for NK Cell Therapies

CHI 2nd Annual Emerging Immuno-Oncology Targets Conference, Boston, MA

• NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity

Society for Immunotherapy in Cancer (SITC) 32nd Annual Meeting, National Harbor, MD

• Poster #P332: Pre-clinical efficacy and tolerability of NKTR-255, a polymer-conjugated IL-15 for immuno-oncology, Kirk, P., et al.

2017 American Association for Cancer Research (AACR) Annual Meeting

• Abstract 1603/Poster 11: NKTR-255 engages the IL-15 pathway driving CD8 T cell survival and CD8 memory T cell proliferation

2016 SITC Annual Meeting

• Poster: NKTR-255: an IL-15-based therapeutic with optimized biological activity and anti-tumor efficacy

2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Abstract 1086: NKTR-288, a PEGylated Interferon Gamma Drug Candidate for the Treatment of Cancer, Hamel, D., et al.

2022 Multidisciplinary Head and Neck Cancers Symposium (MHNCS)

• Poster 83P: TiP Poster 155: A phase 2/3, randomized, open-label study of bempegaldesleukin plus pembrolizumab versus pembrolizumab alone in first-line treatment of patients with metastatic or recurrent head and neck squamous cell carcinoma with PD-L1-expressing tumors (PROPEL-36)

2022 Future Oncology

• Publication: PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

2021 ESMO Immuno-Oncology (ESMO IO) Congress

• Poster 140P: 172 Preliminary Results from PROPEL: A Phase 1/2 Study of Bempegaldesleukin (BEMPEG: NKTR-214) Plus Pembrolizumab With or Without Chemotherapy in Patients with Metastatic NSCLC

2021 European Society for Medical Oncology (ESMO) Congress

• Poster 83P: Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10

2021 Journal of Clinical Oncology

• Publication: Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

2021 Journal for ImmunoTherapy of Cancer

• Publication: Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice

2021 World Congress of Melanoma (WCM)

• Poster P-042: Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study, A. Diab, et al.
• TiP Poster P-047: PIVOT-12: a Phase 3 randomized study of adjuvant bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) versus NIVO in completely resected cutaneous melanoma at high risk for recurrence, A. Eggermont, et al.

2021 Annual Reviews

• Publication: Interleukin-2 (IL-2) Review: This review provides an overview of recent studies that elucidate the potential of newly engineered IL-2-based therapeutics for cancer and autoimmune diseases.

2020 World Conference on Lung Cancer Singapore

• Presentation: P77.04 (Trials in progress (TiP) poster): “PROPEL: A phase 1/2 trial of bempegaldesleukin (BEMPEG; NKTR-214) plus pembrolizumab in lung cancer and other advanced solid tumours)”, D.R. Spigel, et al.

2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Presentation: Progression-free Survival and Biomarker Correlates of Response With BEMPEG Plus NIVO in Previously Untreated Patients With Metastatic Melanoma: Results From The PIVOT-02 Study
• Presentation: Phase 1 Dose-Escalation Study of NKTR-262, a Novel TLR7/8 Agonist, Plus Bempegaldesleukin: Local Innate Immune Activation and Systemic Adaptive Immune Expansion for Treating Solid Tumors
• Abstract 451: Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity, Rolig, A., et al.Oral presentation/Abstract #28

2020 Cancer Discovery

• Publication: PIVOT-02 Dose Escalation: This publication includes safety, tolerability, and clinical activity from the PIVOT-02, a single-arm, Phase I dose-escalation trial (NCT02983045), treatment with the CD122-preferential IL-2 pathway agonist bempegaldesleukin plus nivolumab in patients with immunotherapy-naïve advanced solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer.

2020 Future Medicine

• Publication: PIVOT-10: Design and rationale for the phase 2, single-arm PIVOT-10 study of bempegaldesleukin in combination with nivolumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (NCT03785925).
• Publication: PIVOT IO 001 (Mel): Design and rationale for the randomized, open-label, Phase 3 PIVOT IO 001 study of bempegaldesleukin, a first-in-class CD122-preferential IL-2 pathway agonist, plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma (NCT03635983).

2020 Genitourinary Cancers Symposium

• Abstract TPS589: PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).
• Abstract TPS763: PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator’s choice) in patients with previously untreated advanced renal cell carcinoma (RCC).

Nature Communications – January 31, 2020

• Manuscript: Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
• Manuscript: Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

Kidney Cancer Journal

• Case Study: Revisiting IL-2 Therapy in Renal Cell Carcinoma: A Case Report of a Patient Treated With Pegylated IL-2, Bempegaldesleukin (NKTR-214) – pages 105-107

ESMO Immuno-Oncology Congress 2019

• TiP Poster 127TiP: PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours, Schwarz, J., et al.

2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Abstract P623: Bempegaldesleukin in combination with local radiation and systemic checkpoint blockade induces a robust systemic anti-tumor immunity, Pieper, A., et al.
• Abstract P387: (Trials in Progress): A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer (PORTER), Nissola, L., et al
• Oral Abstract O35: Clinical activity, including deepening of response, of BEMPEG plus NIVO in previously untreated patients with metastatic 1L Melanoma: results from the Phase 1/2 PIVOT-02 Study

Fifth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

• Poster A001: Clinical activity of BEMPEG plus NIVO observed in metastatic TNBC: preliminary results from the TNBC cohort of the Ph1/2 PIVOT-02 study Tolaney, S., et al.

2019 ASCO Annual Meeting

• Abstract #2623/Poster Board #267: Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab, Hurwitz, M., et al.
• Abstract #2584/Poster Board #228: Overcoming genetically-based resistance mechanisms to PD-1 blockade, Torrejon, D., et al.
• Abstract #11010: Pilot study of bempegaldesleukin (NKTR-214) and nivolumab in patients with sarcomas, D’Angelo, S., et al.
• Abstract TPS9601/Poster Board #168b (Trials in progress (TiP) abstract): CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL), Khushalani, N., et al.
• Abstract TPS4595/Poster Board #416b (Trials in progress (TiP) abstract): A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator’s choice) in patients with previously untreated advanced renal cell carcinoma, Tannir, N., et al.

Cancer Discovery

• A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

AACR 2019

• Abstract 3210/Poster Board 20: A potential immunotherapeutic approach for the treatment of osteosarcoma, Wahba, A., et al.
• Abstract 2256/Poster Board 15: Combination of neoantigen DNA plasmid vaccine VB10.NEO and NKTR-214, a CD122-biased immunostimulatory cytokine, induces strong neoantigen-specific T cell responses and sustained tumor regression in pre-clinical models, Granum, S., et al.

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

• Oral presentation/Abstract #28: Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial)., Diab, A.

2019 Genitourinary Cancers Symposium (ASCO-GU)

• Abstract #388: Bempegaldesleukin (NKTR-214) + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02, Siefker-Radtke, A., et al.

SITC 2018

• Oral Abstract #O4: Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma,, Diab, A., et al.
• Abstract #P424: NKTR-214, an engineered IL-2, selectively depletes intratumoral Tregs and expands immunotherapy-induced effector T cell responses, Sharma, M., et al.
• Abstract #P368: Combination of a Dipeptidyl Peptidase Inhibitor BXCL701 and Biased CD122 Agonist NKTR-214 with Anti-PD1 Provides Functional Immunological Memory through Inflammatory Cell Death, MacDougall, J., et al.
• Abstract #P348: Survival and immune modulation in homologous recombination deficient murine ovarian tumors using the PARP inhibitor, rucaparib and immune agonist, NKTR-214, Charych, D., et al.
• Abstract #P419: NKTR-214 in combination with radiation produces a potent in situ vaccine in the syngeneic B78 melanoma model, Sondel, P., et al.
• Abstract #P557: Overcoming genetically-based resistance mechanisms to PD-1 blockade, Torrejon, D., et al.
• Abstract #P364: Systemic anti-tumor immunity and immune memory formation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214, Kivimae, S., et al.
• Abstract #P378: NKTR-214 (CD122-biased agonist) and NKTR-262 (TLR7/8 agonist) combination treatment pairs local innate immune activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity, Rolig, A., et al.

2018 ESMO Congress

• Poster 446TIP: REVEAL: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies, Diab, A., et al.

2018 American Conference on Pharmacometrics (ACoP), San Diego, CA

• Poster W-019: Mechanistic modeling of receptor pharmacology of NKTR-214, a new kinetically-controlled CD122 agonist for cancer immunotherapy

SMI Immuno-Oncology Conference, London, UK

• NKTR-214: Enhanced cancer vaccine effectiveness with NKTR-214, a CD122-biased cytokine

2018 ASCO Annual Meeting

• Oral Abstract 3006: Bempegaldesleukin (NKTR-214) + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02, Siefker-Radtke, A., et al.
• Abstract #3085/ Poster Board #299: Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors, Rastelli, L., et al.
• Abstract #2567/Poster Board #393: TAK-659 in Combination with NKTR-214 and anti-PD-1 Therapy Leads to Complete and Sustained Tumor Regression and Immune Memory In Pre-Clinical Syngeneic Models, Huck, J., et al.
• Abstract #TPS3115/Poster Board #322a: PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors, Vaena, D., et al.
• Abstract #5582/Poster Board #309: Efficacy and immune modulation of the tumor microenvironment in murine ovarian tumor with the PARP inhibitor rucaparib and CD122-biased immune agonist NKTR-214, Simmons, A., et al.

2018 American Association for Cancer Research (AACR) Annual Meeting

• Abstract 123/Poster 13: Enhanced anti-tumor activity of the combination of entinostat and NKTR-214 in renal and colon cancer tumor models
• Abstract 3566/Poster 4: Enhanced expansion and tumor targeting of adoptively transferred T cells with NKTR-214
• Abstract 3755/Poster 5: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214

2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

• Presentation: Phase 1 Dose-Escalation Study of NKTR-262, a Novel TLR7/8 Agonist, Plus Bempegaldesleukin: Local Innate Immune Activation and Systemic Adaptive Immune Expansion for Treating Solid Tumors
• Abstract 451: Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity, Rolig, A., et al.Oral presentation/Abstract #28

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

• Oral presentation/Abstract #28: Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial), Diab, A.

SITC 2018

• Abstract #P364: Systemic anti-tumor immunity and immune memory formation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214, Kivimae, S., et al.
• Abstract #P378: NKTR-214 (CD122-biased agonist) and NKTR-262 (TLR7/8 agonist) combination treatment pairs local innate immune activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity, Rolig, A., et al.

2018 ESMO Congress

• Poster 446TIP: REVEAL: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies, Diab, A., et al.

2018 American Association for Cancer Research (AACR) Annual Meeting

• Abstract 2755/Poster 17: NKTR-262: Prodrug pharmacokinetics in mice, rats, and dogs
• Abstract 3755/Poster 5: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214

Society for Immunotherapy in Cancer (SITC) 32nd Annual Meeting, National Harbor, MD

• Poster #P275: Harnessing the innate and adaptive immune system to eradicate treated and distant untreated solid tumors, Kivimae, S., et al., Langowski, J., et al.

World Preclinical Congress 2017

• NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology

2021 World Congress of Melanoma (WCM)

• Poster P-075: “Benchmarking efficacy outcomes for patients with relapsed/refractory advanced melanoma previously treated with immunotherapy: utility of a systematic pooled clinical analysis”, M. Muhsin, et al.